Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897148 | 0.86 | CYP19A1 (0.34) | BRD4 | |
| SCHEMBL2895211 | 0.80 | PTGER1 (0.33) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL646808 | 0.73 | PTGER1 (0.40) | PTGER1CYP2C9BRD4PPARA | |
| SCHEMBL11959262 | 0.67 | BRD4 (0.51) | PTGER1CYP2C9BRD4PTGER4PTGER3 | |
| SCHEMBL649118 | 0.65 | MRGPRX4 (0.33) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL2897305 | 0.65 | PTPN1 (0.40) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL3926769 | 0.64 | NAMPT (0.39) | PTGER1CYP2C9 | |
| SCHEMBL4310760 | 0.62 | ATM (0.40) | PTGER1CYP2C9PPARA | |
| SCHEMBL647699 | 0.62 | BRD4 (0.41) | PTGER1BRD4 | |
| SCHEMBL7342794 | 0.62 | BRD4 (0.68) | PTGER1CYP2C9BRD4PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-1963293-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067612-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | PTGER1 760/4885CYP2C9 3656/4885BRD4 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.